Bionano Genomics, Inc.BNGO

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · bionano.com

Bionano Genomics provides optical genome mapping solutions, including its Saphyr and Stratys systems and associated consumables and software, used to detect and analyse structural variation in the genome for research and clinical laboratories.

Key ratios

FCF / Sales

-67.9%TTM

2025 -57.3%2024 -224.3%2023 -351.3%

Net margin

-106.6%TTM

2025 -92.6%

ROA

-32.6%TTM

2025 -27.7%2024 -37.4%2023 -33.2%

ROE

-83.6%TTM

2025 -66.2%2024 -170.3%2023 -134.6%

Revenue growth

10.0%TTM

2025 -7.4%2024 -14.8%2023 29.9%

Recent news

Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia 2026-09-14 · GlobeNewswire

Track BNGO in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer